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The classic neuropathological diagnostic markers for AD are amyloid plaques and neurofibrillary tangles, but their role in the etiology and
progression of the disease remains incompletely defined. Research over the last decade has revealed that cell cycle abnormalities also represent a
major neuropathological feature of AD. These abnormalities appear very early in the disease process, prior to the appearance of plaques and
tangles; and it has been suggested that neuronal cell cycle regulatory failure may be a significant component of the pathogenesis of AD. The
amyloid precursor protein (APP) is most commonly known as the source of the β-amyloid (Aβ) peptides that accumulate in the brains of patients
with AD. However, a large body of work supports the idea that APP is also a signaling receptor. Most recently, it has been shown that familial AD
(FAD) mutations in APP or simple overexpression of wild type APP cause dysfunction of APP signaling, resulting in initiation of DNA synthesis
in neurons and consequent apoptosis. In this article, we review the evidence that APP has the potential to activate aberrant neuronal cell cycle re-
entry in AD, and we describe a signal transduction pathway that may mediate this abnormal activation of the cell cycle.
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AD is a progressive, incurable disease that always ends in
death. Its predominant clinical manifestation is memory loss,
but a number of other changes in brain function, including
disoriented behavior and impairments in language, comprehen-
sion, and visual–spatial skills, also characterize this disorder.
The diagnostic hallmarks of AD, namely neuronal attrition,
amyloid deposits, and neurofibrillary tangles, have not as yet
explained the etiology and pathogenesis of the disease.
However, additional markers of AD have been described that
may give some clues to the mechanism by which neurons die in
AD brain. Notably, aberrant expression of cell cycle proteins
and DNA tetraploidy in neurons in pathologically affected
regions of AD brain have been described. It has been shown
also that those neurons that have entered the cell cycle
subsequently undergo a form of programmed cell called⁎ Corresponding author. MRC 223, McLean Hospital, 115 Mill Street,
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doi:10.1016/j.bbadis.2006.10.008apoptosis. By now, the evidence that neuronal death in AD
may be at least partly due to cell cycle entry followed by
apoptosis, is considerable. This has clear therapeutic implica-
tions: understanding the molecular pathways underlying this
cell cycle-mediated neurodegeneration will reveal new ther-
apeutic targets and lead to novel strategies for slowing or even
blocking the onset and progression of AD. One such pathway,
that is mediated by APP, will be described.
2. Cell cycle abnormalities in AD
2.1. The cell cycle is activated in neurons in AD brain
A decade ago, Vincent and Davies showed definitively that
activation of cell cycle components occurred in AD brain [1].
Subsequently, abnormal expression of such cell cycle molecules
as cdc2, cdk4, p16, Ki-67, cyclin B1, and cyclin D was reported
in pathologically affected or vulnerable neurons in AD brain
[2–6]. Busser et al. [6] found ectopic expression of cell cycle
proteins in regions of AD brain displaying extensive cell death,
and Chow et al. [7] detected increased expression of genes
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relative to early-stage AD brain. A number of these cell cycle
regulators have been reported to appear in vulnerable neurons
prior to lesion formation [6,8,9].
These data showed correlations between the expression of cell
cycle markers and AD neuropathology, but did not reveal the
consequences for AD neurodegeneration of such activation of cell
cycle proteins. Yang et al. [10] showed that one of these
consequences appears to be that vulnerable neurons in AD brain
re-enter the cell cycle. This report demonstrated that a significant
number of hippocampal pyramidal (4% vs. 0% in control
hippocampus) and basal forebrain neurons in AD brain had
undergone full or partial DNA replication, evidence that these
neurons had completed the S phase of the cell cycle. Such DNA
synthesis is not normally seen in neurons; and indeed, it was not
detected in regions of AD brain untouched by pathology or in
control brains. Yang et al. [10] suggested that the state of
tetraploidy eventually is lethal to neurons. In a follow-up report,
this same group [11] described the emergence of cell cycle-related
proteins prior to neuronal cell death not only in the brains of
individuals with advanced AD, but also in the brains of
individuals with mild cognitive impairment, which usually
progresses to AD. Yang and co-authors went on to describe the
reexpression of cell cycle markers in four different plaque-bearing
mouse models of AD [12]. In one of these models, cell cycle
events were detected many months before the first appearance of
plaques. These in vivo observations supported reports showing
that at least two in vitro models for AD neurodegeneration
featured re-activation of cell cycle entry in neurons [13,14].
2.2. Cell cycle activation may link to tangles in AD
Activation of the cell cycle may also contribute to the
formation of neurofibrillary tangles, which are pathological
markers for AD that contain hyperphosphorylated microtubule
associated protein tau. The phosphoepitope S214 of tau, that
appears in neurofibrillary tangles in AD, is a prominent
phosphorylation site in metaphase but not in interphase of
dividing cells expressing tau [15]. The tau TG3 epitope
(phosphorylated T231) has been detected in mitotic cells but
not in quiescent cells [1]. Moreover, tau is hyperphosphorylated
during mitosis in neuroblastoma cells [16], and a cdc2-related
kinase is associated with paired helical filaments, the ultra-
structural correlates of neurofibrillary tangles, in AD brain [17].
Patrick et al. (1999) showed that activation of the p25/Cdk5
complex results in hyperphosphorylation of tau and reduces the
ability of tau to associate with microtubules. Mitotic phosphor-
ylation of tau likely causes conformational changes, which may
be associated with the development of neurofibrillary tangles.
These data support the idea that reactivation of the cell cycle
machinery not only causes DNA synthesis but also may cause
tau hyperphosphorylation in AD brain.
2.3. Cell cycle activation may lead to apoptosis in AD brain
Activation of cell cycle proteins in neurons also can, under
certain circumstances, lead to a form of cell suicide calledapoptosis (reviewed in ref. [18]). The possibility that such a
process occurs in AD brain was first suggested by Su et al. [19],
when they reported evidence for DNA fragmentation in neurons
in AD brain. This same group showed that β-amyloid induces
neuronal apoptosis in vitro [20], a finding that has been
replicated in many laboratories. In support of the idea that
apoptosis may be one means by which neurons die in AD,
several groups have reported the presence of activated caspases
in the postmortem brains of individuals with AD [21–23], and
have described apoptotic neurons in the brains of transgenic
mouse models for AD [24–27]. Apoptosis normally proceeds to
completion within 16–24 h, which seems incompatible with the
relatively slow progression of AD. However, Cotman [28] and
Raina et al. [23] have both proposed that the induction of
compensatory responses to apoptosis in the AD brain protects
the neurons from terminal apoptosis, and that a dynamic balance
between cell death processes and compensatory responses
exists in AD brain.
3. APP signaling pathways that mediate cell cycle
activation
3.1. APP is a signaling protein
The amyloid precursor protein (APP) is the source of the β-
amyloid peptides that accumulate in the brains of patients with
Alzheimer's disease (AD). The primacy of APP in the etiology
of AD is underscored by the fact that virtually all individuals
with Down syndrome (DS), who as a consequence of
chromosome 21 trisomy overexpress APP, develop AD by the
age of 40. This finding, together with the observation that either
specific mutations in APP or simple duplication of the wild type
APP gene can cause some forms of FAD [29,30], suggests the
possibility that an alteration in the normal function of APP may
occur in AD, and has refocused attention on the delineation of
the function that APP subserves in the brain.
The notion that APP may be a signaling receptor was
originally proposed on the basis of the predicted amino acid
sequence of APP, which suggested that APP was a type 1
intrinsic membrane protein whose structure was consistent with
that of a “cell surface receptor” [31]. The first direct evidence in
support of this idea was the finding that the APP cytodomain
interacted with and activated the heterotrimeric G protein Go
[32], a finding that was subsequently confirmed independently
[33]. During the last decade, a multitude of additional cytosolic
proteins that interact with the APP cytodomain have been
described [14,34–43], suggesting that APP has versatile
signaling roles.
To define neuronal signaling pathways that may be mediated
by APP, we established an in vitro paradigm for AD neuro-
degeneration, in which wild type or FAD APP cDNAs were
expressed as transgenes in primary cortical neurons [14,44].
Using this model, we showed that overexpression of wild type or
evenmodest expression of FADmutants of APP in neurons leads
to neuronal DNA synthesis and apoptosis [14,44], suggesting
that an APP-mediated signaling pathway may play a role in the
cell cycle activation and neurodegeneration seen in AD.
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As a first step in defining neuronal signaling pathways that
may be initiated by APP, a search of brain cDNA libraries was
carried out to detect genes encoding proteins that interact with
the cytodomain of APP [14,43]. One of these, APP–BP1, was
found to be an essential cell cycle protein that drives the cell
cycle through the S-M checkpoint in dividing cells, but which
causes apoptosis when overexpressed in neurons [44]. Over-
expression of wild type APP or expression of FAD mutants of
APP in neurons, using the paradigm described above, resulted
in an increase in expression of APP–BP1 in lipid rafts, followed
by entry of the neurons into the S phase of the cell cycle, and
neuronal apoptosis [44]. As predicted by these in vitro results,
APP–BP1 was shown to be overexpressed in lipid rafts in at-
risk regions of human AD brain relative to cognitively intact
controls [45]. Consistent with these observations, modest
overexpression of APP–BP1 in neurons, sufficient to mimic
the observed increases of this protein in lipid rafts in AD brains,
caused neuronal cell cycle entry and apoptosis [45].
The interaction of APP with APP–BP1 activates a pathway
leading to the conjugation of NEDD8, a ubiquitin-like protein,
to its target (Fig. 1, ref. [44]). APP–BP1, together with hUba3,
is functionally analogous to the ubiquitin activating enzyme E1,
with hUba3 containing the active cysteine and ATP binding site.
When NEDD8 is activated by the APP–BP1/hUba3 complex, it
forms a thiol ester bond with hUbc12, which has a function
parallel to that of ubiquitin-conjugating enzyme Cdc32.
Subsequently, NEDD8 is covalently coupled to lysine residues
in its target proteins [46]. So far, the proteins known to beFig. 1. Graphic representation of the neddylation pathway activated by the
interaction of APP with APP–BP1. Steps in the cascade that are potential
therapeutic targets include the interaction between APP and APP–BP1, and the
interaction of APP–BP1/hUba3 with the conjugating enzyme hUbc12.neddylated via this pathway are a family of proteins called
cullins [47] and the Mdm2 oncogene product, which in turn
regulates neddylation of the cell cycle protein p53 [48]. Cullins
are scaffold proteins for the E3 ubiquitin ligase complex, and
neddylation of cullin enhances its ability to promote ubiquitina-
tion [49,50]. Indeed, NEDD8 has been found in ubiquitinated
neurofibrillary tangles in AD brain [51]. NEDD8 signalling has
been shown to regulate protein degradation pathways partici-
pating in cell cycle progression [52–55]. The discovery of a
novel protein, NUB1, which recruits NEDD8-conjugates to the
proteasome for degradation, provides a direct link between
these two systems [56,57]. Inhibition of the neddylation
pathway in neurons by expression of a dominant negative
mutant of hUbc12 prevents FAD APP-mediated cell cycle entry
and apoptosis [44,45]. Thus, elements of this pathway are
attractive targets for potential therapies aimed at preventing
neurons in AD brain from entering the cell cycle.
3.3. p21 activated kinase 3 mediates neuronal DNA synthesis
caused by FAD mutants of APP
In addition to APP–BP1, the p21-activated kinase PAK3
also was shown to bind to the C-terminus of APP [14]. PAK3 is
a serine/threonine kinase whose activity is regulated by the p21
family of small GTPases. Mutations in this molecule, which is
expressed selectively in the nervous system [14], cause one
form of X chromosome-linked mental retardation [58,59].
PAK3 is involved in the control of cytoskeleton dynamics,
possibly affecting cognition by regulating the shape of
neuronal synapses. Consistent with this idea, mice lacking
the Pak3 gene are impaired in both synaptic plasticity and
cognition [60].
PAK3 also has been implicated in the abnormal DNA
synthesis and apoptosis caused by overexpression of wild type
APP or ectopic expression of FADmutants of APP in neurons in
vitro [14]. A graphic representation of the neuronal signaling
pathway activated by interaction of FAD APP with PAK3 is
shown in Fig. 2. A dominant negative kinase-dead mutant of
PAK3 inhibits wild type or FAD APP-mediated neuronal
apoptosis and DNA synthesis in our in vitro model; this effect is
abolished by deletion of the PAK3 APP-binding domain or by
co-expression of a peptide representing this binding domain
[14]. These data suggest that both the kinase activity of PAK3
and also its interaction with APP are important for the FAD APP
signaling pathway. The specificity of PAK3 involvement in
FAD APP-mediated apoptosis rather than in general apoptotic
pathways is suggested by the facts that a constitutively active
mutant of PAK3 does not alone cause neuronal apoptosis, and
that the dominant negative mutant of PAK3 does not inhibit
chemically-induced apoptosis. In vitro, FAD APP-mediated
DNA synthesis precedes FAD APP-mediated apoptosis in
neurons; and inhibition of neuronal entry into the cell cycle
blocks the apoptosis [14].
Pertussis toxin inhibits DNA synthesis and apoptosis caused
in vitro by FAD APP mutants, implicating Go in the process as
well [14]. These data are consistent with the reports by
Nishimoto and colleagues that the His657–Lys676 domain of
Fig. 2. Graphic representation of the signaling pathway activated by the
interaction of PAK3 with APP and Go. Steps in the cascade that are potential
therapeutic targets include interactions among APP, Go and PAK3 or the activity
of JNK3.
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in a GTPγS-inhibitable manner [32,61]. Their demonstration
that an antibody to the extracellular domain of APP that acts as a
ligand mimetic [62] causes activation of Go, argues that APP
may be a G protein-coupled receptor. Notably, neuronal ex-
pression of FAD APP deleted for residues His657–Lys676 does
not cause cell cycle entry [14].
These data support a model in which APP normally is part of
a Go protein-centered complex including PAK3 that transduces
extracellular signals to the cytoplasm (Fig. 2), and in which
overexpression of wild type APP or expression of FAD APP
causes dysfunction of this pathway. How might this complex be
related to the pathway activated by APP–BP1? At least one of
the downstream molecules in the PAK3-mediated pathway is
the c-Jun N-terminal kinase 3 (JNK3). A dominant negative
mutant of JNK3 inhibits FAD APP-mediated cell cycle entry,
while a constitutively active mutant of JNK3 alone causes
neuronal DNA synthesis (McPhie, D.L. and Neve, R.L.,
unpublished data). The effect of the constitutively active
JNK3 is not blocked by a dominant negative mutant of
PAK3, implying that the action of JNK3 is downstream of
PAK3. However, inhibition of the APP–BP1-mediated neddy-
lation pathway in neurons by expression of a dominant negative
mutant of hUbc12 prevents constitutively active JNK3 activa-
tion of neuronal cell cycle entry (Chen, Y. and Neve, R.L.,
unpublished data). Whereas pertussis toxin blocks neuronalDNA synthesis caused by ectopic expression of FAD APP, it
does not block neuronal DNA synthesis caused by APP–BP1.
These data suggest that the order of events in the FAD APP-
mediated pathway leading to neuronal cell cycle entry and
apoptosis consists of formation of the APP-Go–PAK3 complex,
followed by activation of JNK3, which is then followed by
activation of the APP–BP1 neddylation pathway. Intermediate
events are likely to occur.
These findings also implicate JNK3 in FAD APP-mediated
neuronal DNA synthesis and apoptosis, and are consistent with
the finding that JNK3 is highly expressed and activated in
postmortem brains of individuals with AD [63]. JNK3 is
associated with neurofibrillary tangles, and JNK upregulation
colocalizes with phosphorylated tau [63], a microtubule
associated protein which has been shown to be phosphorylated
by JNK [64]. Abnormal phosphorylation of tau by JNK3 causes
the formation of oligomeric tau fibrils that have been termed
“pretangles” [65]. In a transgenic mouse model of AD, JNK
activation is associated with amyloid deposits and phospho-tau.
Age-dependent increased JNK activity is correlated not only
with increased amyloid deposition in this mouse model, but also
loss of functional synapses similar to that observed in AD brain
[66].
We and others have hypothesized that APP and its C-
terminal binding proteins – among them Go, PAK3, and APP–
BP1 – have a regulated interaction that activates signaling
pathways important for normal brain function, perhaps mediat-
ing synaptic remodeling or neurogenesis during learning. In
analogy with the cell proliferation and resultant tumorigenesis
caused either by a constitutively active mutant of the epidermal
growth factor receptor (EGFR) or by sustained overexpression
of wild type EGFR (Lorimer, 2002), neuronal cell cycle entry
and consequent apoptosis may be caused either by constitutive
activation of APP signaling pathways in neurons due to FAD
mutations in APP or by sustained overexpression of wild type
APP. Thus, therapeutic reagents that target these signaling
pathways may have efficacy in treating AD neurodegeneration.
3.4. APP-C31 may mediate neuronal cell cycle entry and
neurodegeneration in AD brain
All but one of the binding proteins for the APP cytodomain
interact with APP within the last 31 amino acids of this domain.
Why is this important? For one thing, C31 can be generated
from APP by caspase cleavage [67,68]. Furthermore, this
cleavage has functional significance, in that expression of C31
alone has been shown to cause neuronal DNA synthesis and
apoptosis [14,45,68]. Recently, inhibition of C31-producing
caspase cleavage of APP was shown to prevent the development
of AD-like pathology and behavior caused by two FAD
mutations of APP [69]. A D664A mutation (which prevents
the generation of C31) was introduced into the background of a
human APP minigene carrying the K670N/M671L (Swedish)
and V717F (Indiana) mutations. Both the original FAD mutant
minigene (PDAPP) and also the D664A version of it [PDAPP
(D664A)] were expressed in transgenic mice under the control
of the PDGF B-chain promoter.
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neither altered the net in vivo production of Aβ40 and Aβ42,
nor affected the extent of amyloid plaque deposition in the
brains of PDAPP(D664A) mice compared to PDAPP mice.
However, the D664A mutation did have an effect on
neurodegeneration and on behavior. The PDAPP mice without
the D664A mutation displayed decreased hippocampal pre-
synaptic density number relative to controls at 8–10 months of
age, a pronounced increase in GFAP immunoreactivity in the
hippocampus by 12 months, a loss in dentate gyrus volume at
3 months, learning and spatial impairments at 12 months, and an
increase in the number of proliferating cells present in the
subgranular zone of the dentate gyrus at both 3 and 12 months.
In contrast, the PDAPP(D664A) mice, with the D664A
mutation, were indistinguishable from controls in every one
of these parameters.
It can be inferred from these data that the mutation Asp664
“rescues” multiple aspects of neuropathology and impaired
learning that are normally caused by the Swedish and Indiana
mutations in APP. In other words, if C31 cannot be generated,
the FAD APP mutations cannot cause certain pathological and
behavioral abnormalities. What are the implications of these
findings? First of all, note that Asp664 selectively rescues the
neurodegeneration and the learning abnormalities of the
PDAPP mice without decreasing the production of Aβ40 or
Aβ42. Thus, the rescue is independent of the production of Aβ.
Secondly, the C31 region of APP encompasses the binding sites
for nearly all of the signaling proteins, including APP–BP1 and
PAK3, that have been shown to bind to the intracellular domain
of APP.
The data suggest a scenario in which C31, when removed
from APP, abnormally activates or disrupts signaling pathways
mediated by APP. One possibility is that the signaling initiatedFig. 3. Schematic of a signal transduction pathway activated by FADmutations of AP
ligand (portrayed in the figure as a trapezoid). FAD APP is relieved of such constrain
synthesis and apoptosis.by interaction of the APP C-terminal domain with signal
transduction proteins normally is tightly regulated by binding of
ligand(s) to its extracellular domain [variously identified as F-
spondin [70], notch [71,72], TGF-β2 [73], and even Aβ
[74,75]. In such a scenario, as suggested by McPhie et al. [14],
C31, when not attached to APP, is relieved of the normal
constraints imposed on it when the extracellular domain of APP
is not occupied by a ligand, and becomes constitutively active or
else takes on signaling functions that it does not normally
possess (Fig. 3).
To test the idea that C31 becomes constitutively active, one
may ask whether causing APP signaling to become tonically
active results in the same consequences for the neuron that
expression of C31 alone does. It has been found that exposure
of neuronal cells to the antibody 22C11, raised against the
extracellular domain of APP, causes constitutive activation of
Go [62] which is known to bind to and be activated by APP
[32,33]. In this context, 22C11 could be considered to be an
APP ligand mimetic of sorts. Indeed, sustained exposure of
neurons to 22C11 causes DNA synthesis [14] and neuronal
apoptosis [14,76,77] via the APP–BP1- and PAK3- mediated
signal transduction pathway that is activated by C31 alone
[14].
4. Concluding remarks
We have proposed that, in neurons, APP is a signaling
receptor whose normal function is tightly regulated by ligand
binding (Fig. 3). We hypothesize that this normal, regulated
function is altered by overexpression of wild type APP or by
expression of FAD mutants of APP, leading to neuronal cell
cycle entry and consequent apoptosis. We have reported
previously that, in contrast to FAD mutant APPs, neither wildP. In the normal cell, the function of APP is tightly regulated by the binding of its
ts, and, together with PAK3, Go, and APP–BP1, causes aberrant neuronal DNA
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[78]. In addition, we have shown (McPhie, D.L. and Neve, R.L.,
unpublished data) that neither wild type nor FAD mutant
presenilin causes aberrant neuronal cell cycle entry. It is worth
noting that expression of FAD APP leads to increased levels of
secreted α-APP and β-APP, and to elevation of levels of
specific C-terminal fragments of APP in addition to Aβ, while
the only known effect of FAD presenilins on APP processing is
alteration of the ratio of Aβ [42] to Aβ [40]. These data suggest
that fragments of APP other than Aβ may play a role in
abnormal neuronal cell cycle entry and consequent apoptosis,
and also suggest that there is more than one pathway to
neurodegeneration in AD.
These data highlight the importance of understanding the
normal function of APP in the brain and how this function may
be disturbed in AD.
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